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apid real time surveillance and monitoring of pandemic
nﬂuenza associated pneumonia & risk factors using pri-
ary care electronic medical records (EMR)
. Wong1, J.G. Mercer2, S. Mukhi1, S. Totten1,∗, K. El
man3, G. Jayaraman1, C. Babin1, R. Saginur3, R. Kropp1,
. Rodin1, G. Garber3
Public Health Agency of Canada, Ottawa, ON, Canada
Canadian Medical Association, Ottawa, ON, Canada
University of Ottawa, Ottawa, ON, Canada
Background: The arrival of the inﬂuenza pandemic
pH1N1) highlights gaps in surveillance. This pilot project
everages EMR to rapidly detect changes in the severity of
nﬂuenza-like-illness (ILI) and associated risk factors to sup-
ort public health actions.
Methods: The sentinel primary care clinics use their
MR with minimal operational disruption to transmit de-
dentiﬁed surveillance information daily to the secure
anadian Network for Public Health Intelligence (CNPHI)
erver at the Public Health Agency of Canada. The Canadian
luWatch ILI case deﬁnition is used:
fever (T > 38 0C) and
cough and
myalgia or arthralgia or sore throat or fatigue.
Chi-Square, Fisher Exact and Mann-Whitney tests, with
< 0.05 (2-sided) denoting statistical signiﬁcance are used.
Results: During the initial phase of the 12 month study
Oct 4-Nov 19, 2009), 237 medicallyattended ILI (MA-ILI)
ases arising from 12,581 patient visits were reported from
articipating Canadian sentinel sites. Children under 10
ears accounted for 33.8% of these cases. Pneumonia was
eported in 8.4% of the MA-ILI cases, increasing from none
n early October to 22.2% in the second week of Novem-
er. Comparing ILI cases with pneumonia to those without,
he median age was 30 years vs 21 years (p = 0.5); 50.0% vs
4.5% were females (p = 0.2); 0% vs 0.9% were health care
orkers (p = 1.0); median time from symptom onset to pri-
ary care visit was 5 days vs 2 days (p = 0.02); 0% vs 2.3%
eceived the current season’s inﬂuenza vaccine (p = 1.0),
.0% vs 0.5% received the pH1N1 inﬂuenza vaccine (p = 0.2),
5.0% vs 39.4% received a pneumococcal vaccine (p = 0.2);
% vs 3.3% had diabetes (p = 1.0) and 20.0% vs 23.4% had
sthma (p = 1.0).
Conclusion: Children under 10 years were disproportion-
tely affected but most cases were not life threatening. EMR
as able to rapidly detect the shifts in the pandemic severity
n real time. The proportion of ILI cases with pneumonia was
scalating during the initial phase of this study. Pneumonia
as associated with a longer time from symptom onset to
rimary care visit. With increasing sample size in this ongo-
ng study, statistical power to assess vaccine effectiveness
nd severity risk factors is anticipated to increase greatly.
oi:10.1016/j.ijid.2010.02.2209
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6.001
ystemic MRSA infections
. Rubinstein
Faculty of Medicine, Winnipeg, Canada
Systemic Staphylococcal infections were always a
readed complication of various injuries and for many
enturies meant amputation or death for the unfortunate
atient. MRSA has become since the 60’s a major cause for
ystemic infections and in various settings are responsible to
80% of all nosocomial bacteremias. In other settings, MRSA
s responsible ∼50% and in a recent survey of ICU infections
mong ∼14.000 patients the infection rate had decreased to
7% (Vincent et al JAMA 302;2323:2009). MRSA infections are
haracterized by various clinical presentations from mild-
o rapidly progressing and frequently with involvement of
ultiple organs includ. heart valvaes, bones, joints and
mplanted foreign bodies. Those locations, with the partic-
lar resistance pattern of MRSA, and only a few effective
ntibiotics to choose from, make MRSA infections partic-
larly difﬁcult to treat with a frequent need for surgery.
he frequent use of foreign bodies in therapy (IV catheters,
mplants,dialysis catheters, CNS shunts etc’) and the bio-
ogical avidity of this organism to these foreign materials
dd to the complexity of the infection. Quorum sensing and
he ability of the organism to create a bioﬁlm and to detach
rom the adherent colony add also to the complexity of these
nfections. Understanding of these biological mechanisms
nd being able to interfere should allow for some future
herapeutic measures. Evidently, meanwhile, hospital infec-
ion control and a possible future staphylococcal vaccine are
olutions to peruse. CA MRSA can be controlled by hyginic
easures as well as vaccine as this organism despite its low
otential to cause systemic infections is likely to stay for
any years.
oi:10.1016/j.ijid.2010.02.2210
6.002
reatment of severe MRSA infections: Beyond Vancomycin
. Karchmer
Beth Israel Hospital, Boston, MA, USA
Vancomycin, as the gold standard for therapy of severe
RSA infections, particularly pneumonia, bacteremia, and
ndocarditis, has been questioned. In recent years reduced
ancomycin susceptibility of MRSA has been noted: minimum
nhibitory concentrations (MIC) have increased, isolates with
ntermediate susceptibility (MIC 4 to 16 $g/ml) [VISA] and
vertly resistant (MIC ‘‘32 $g/ml) [VRSA] have been noted,
nd importantly isolates of apparently vancomycin sus-
eptible MRSA with subpopulations exhibiting intermediate
usceptibility to vancomycin (survival at vancomycin con-
entrations’’ 4 $g/ml) so called heteroVISA [hVISA] have
een encountered. VISA and hVISA isolates may emerge
hen vancomycin therapy is suboptimal. Severe MRSA infec-
ions caused by isolates with vancomycin MIC’’ 1.5-2.0 $g/ml
nd hVISA have been associated with poor clinical outcome
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when treated with vancomycin compared with infections
caused by more susceptible MRSA. Aggressive vancomycin
dosing to achieve trough concentrations 15 to 20 $g/ml has
been used to improve outcome when treating infections
caused by MRSA. The clinical utility of this strategy has not
been established; however, aggressive dosing is associated
with nephrotoxicity especially in patients weighing > 101 kg,
with reduced renal function and in intensive care settings.
Using vancomycin in combination with other antimicrobials
has not proven more effective either.
Treatment with other antimicrobials to which MRSA are
susceptible is increasingly used to address concerns regard-
ing the inefﬁcacy of vancomycin therapy for severe MRSA
infections. Clinical trials suggest that linezolid is at least
comparable to vancomycin for treatment of MRSA pneumo-
nia and for pharmacokinetic-pharmacodynamic reasons may
be preferable in selected patients. Daptomycin (6mg/kg/d)
was non-inferior to comparator regimens (low-dose gentam-
icin plus nafcillin or vancomycin) in a clinical trial treating
S. aureus bacteremia and right sided endocarditis; cure
rates were higher with daptomycin compared to vancomycin
(not statistically signiﬁcant) in trial patients with MRSA
bacteremia. Doses of daptomycin (10mg/kg/d) higher than
approved by the FDA are preferred by some experts when
treating MRSA bacteremia or endocarditis. Linezolid has
appeared effective in selected patients with persistent MRSA
bacteremia. Televancin, with dual mechanisms of cidality
versus MRSA, has recently been approved by the FDA for
treatment of complicated skin/soft tissue infection due to
MRSA and may offer additional options for treating severe
infections. New cephalosporins that bind to PBP2’ and to
which MRSA are susceptible are under development and
fusidic acid is attracting increasing interest as an agent for
combination therapy against severe MRSA infections.
doi:10.1016/j.ijid.2010.02.2211
66.003
The potential for a staphylococcal vaccine
O. Schneewind
University of Chicago, Chicago, IL, USA
Staphylococcus aureus is a frequent cause of bac-
teremia, pneumonia, skin and soft tissue infection as
well as osteomyelitis and septic arthritis. The remarkable
pathogenic potential of this microbe has been demon-
strated over the past decade, with the rapid spread of
highly virulent, drug (methicillin)-resistant S. aureus strains
(MRSA). The search for protective immunity against inva-
sive S. aureus disease has been a research goal since the
discovery of this microbe, however this pursuit has not
yet been successful and a staphylococcal vaccine is cur-
rently not available. To identify protective antigens for a
staphylococcal vaccine, three models systems for S. aureus
infections in mice were developed - pneumonia, lethal sep-
ticemia and persistent abscess model. Using a combination
of molecular genetic tools, the genetic requirements of the
pathogen for each of the three disease complexes were char-
acterized. Genes encoding secreted products that proved
to be necessary for the pathogenesis in any one of three
disease models were examined further, subjecting the puri-
p
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ed products to vaccine trials for protective immunity.
ene products that generated protection were also tested
or cross-protection in other disease models or examined
or speciﬁc animal or human immune responses follow-
ng infection. Taken together these studies revealed that
taphylococci elicit only moderate host immune responses
o infection owing to their expression of several differ-
nt immune-suppressive molecules, in particular adenosine
ynthase AdsA. a-hemolysin was the sole protective anti-
en for staphylococcal lung infection. Antibodies against
eme-iron scavenging factors provided protective immunity
gainst staphylococcal abscess formation, whereas combi-
ations of different antibodies generated protection against
ethal septicemia in mice. These studies therefore suggest
hat the generation of a successful vaccine against S. aureus
nfection requires a combination of different antigens, but
annot be accomplished by a single factor.
oi:10.1016/j.ijid.2010.02.2212
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RSA in Latin America: special considerations
. Guzman-Blanco
Hospital Privado, Caracas, Venezuela
Until the year 2000, epidemiological surveillance in Latin
merica was conducted in only a few countries, includ-
ng Venezuela and Argentina. Since then, with the support
f the Pan American Health Organization (PAHO), a net-
ork for surveillance of bacterial resistance has been
rganized, which includes the majority of Latin American
ountries: the Monitoring/Surveillance Network for Resis-
ance to Antibiotics. Criteria for admission of surveillance
enters to the network include concepts of standardization,
uality control, supervision visits and regular data report-
ng. Results are published each year on the PAHO web site
www.paho.org) .The data are collected during the daily
ork of selected laboratories in the region, with strong sup-
ort from national and regional reference laboratories.
The Resistance Group of the Panamerican Infectious Dis-
ases Asociation, under the leadership of Dr. Jose Maria
asellas has kept surveillance on the incidence of MRSA and
pdated reports are published on the API journal.
The methodology used for deﬁnition of a given strain as
RSA is different in each country. Some countries work with
he Bauer and Kirby method using the oxacillin or cefoxitin
isks, and others use automated methods like VITEK 1 or 2
bioMérieux) and/or MicroScan (Dade Behring).
Conﬁrmation tests such as the methicillin screen plate
est are not widely used. The high cost of E-test strips does
ot permit their routine use in laboratories in the region,
nd rapid methods of mecA gene detection are not available
or the majority of laboratories. Molecular analysis of MRSA
trains is restricted to some centers in Brazil, Argentina,
hile, Mexico and Colombia. In cases of nosocomial out-
reaks, the identity of MRSA strains is usually assumed from
he phenotypic pattern of antibiotic resistance.Nosocomial, multidrug-resistant MRSA is a growing
roblem in Latin America. Information gathered by the
AHO-sponsored program on nosocomial infections demon-
trated that for the year 2004, MRSA prevalence was as
